Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 91 AL 105

The possibility of use of the ketogenic diet and medium chain triglycerides supplementation in the support therapy of Alzheimer disease

Włodarek D.

Curr Opin Clin Nutr Metab Care. 2021 Jul 1;24(4):385-391. doi: 10.1097/MCO.0000000000000752.

Selective Secretase Targeting for Alzheimer's Disease Therapy

Miranda A, Montiel E, Ulrich H, Paz C.

J Alzheimers Dis. 2021;81(1):1-17. doi: 10.3233/JAD-201027.

Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer's Disease (CROSA)

Zhang S, Qi J, Yang Q, Guo Q.

Int Psychogeriatr. 2021 Nov;33(11):1193-1205. doi: 10.1017/S1041610221000247. Epub 2021 Mar 24.

Exposure to gamma tACS in Alzheimer's disease: A randomized, double-blind, sham-controlled, crossover, pilot study

Benussi A, Cantoni V, Cotelli MS, Cotelli M, Brattini C, Datta A, Thomas C, Santarnecchi E, Pascual-Leone A, Borroni B.

Brain Stimul. 2021 May-Jun;14(3):531-540. doi: 10.1016/j.brs.2021.03.007. Epub 2021 Mar 21.

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Koh SH, Kwon HS, Choi SH, Jeong JH, Na HR, Lee CN, Yang Y, Lee AY, Lee JH, Park KW, Han HJ, Kim BC, Park JS, Lee JY, Kim S, Lee KY.

Alzheimers Res Ther. 2021 Mar 26;13(1):66. doi: 10.1186/s13195-021-00803-w.

A systematic review and meta-analysis of the clinical effects of Souvenaid in patients with Alzheimer's disease

Shim Y, Yoon B, Na S, Lim EY, Hong YJ, Yang DW.

Asia Pac J Clin Nutr. 2021;30(1):30-41. doi: 10.6133/apjcn.202103_30(1).0005.

An Efficacy Trial of Long-Term Care Residents With Alzheimer's Disease Using Videos to Communicate Care Preferences

Towsley GL, Wong B, Baier RR, Neller S.

J Am Med Dir Assoc. 2021 Jul;22(7):1559-1560. doi: 10.1016/j.jamda.2021.02.032. Epub 2021 Mar 30.

Prospects of Marine Sterols against Pathobiology of Alzheimer's Disease: Pharmacological Insights and Technological Advances

Rahman MA, Dash R, Sohag AAM, Alam M, Rhim H, Ha H, Moon IS, Uddin MJ, Hannan MA.

Mar Drugs. 2021 Mar 20;19(3):167. doi: 10.3390/md19030167.

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease

Unzeta M, Hernàndez-Guillamon M, Sun P, Solé M.

Int J Mol Sci. 2021 Mar 25;22(7):3365. doi: 10.3390/ijms22073365.

β-Lactolin Enhances Neural Activity, Indicated by Event-Related P300 Amplitude, in Healthy Adults: A Randomized Controlled Trial

Kanatome A, Ano Y, Shinagawa K, Ide Y, Shibata M, Umeda S.

J Alzheimers Dis. 2021;81(2):787-796. doi: 10.3233/JAD-201413.

A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials

O'Bryant SE, Zhang F, Petersen M, Johnson L, Hall J, Rissman RA.

J Alzheimers Dis. 2021;81(2):557-568. doi: 10.3233/JAD-201610.

Multitarget Directed Ligand Approaches for Alzheimer's Disease: A Comprehensive Review

Ramalakshmi N, R S R, C N N.

Mini Rev Med Chem. 2021;21(16):2361-2388. doi: 10.2174/1389557521666210405161205.

Aducanumab for Alzheimer's disease: The never-ending story that nurses should know

Petch J, Bressington D.

Nurs Open. 2021 Jul;8(4):1524-1526. doi: 10.1002/nop2.878. Epub 2021 Apr 7.

Natural products as pharmacological modulators of mitochondrial dysfunctions for the treatments of Alzheimer's disease: A comprehensive review

Jin X, Guo JL, Wang L, Zhong X, Yao WF, Gao H, Liu MY.

Eur J Med Chem. 2021 Jun 5;218:113401. doi: 10.1016/j.ejmech.2021.113401. Epub 2021 Mar 27.

Epigenetic regulation in Alzheimer's disease: is it a potential therapeutic target?

Coppedè F.

Expert Opin Ther Targets. 2021 Apr;25(4):283-298. doi: 10.1080/14728222.2021.1916469. Epub 2021 May 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias